According to a new study, patients receiving six months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent (DES) appeared to have similar outcomes to patients who received DAPT for a full year.

U.S. CoreValve High Risk trial TCT 2014

According to a new study, transcatheter aortic valve replacement (TAVR) provided meaningful clinical benefits relative to surgical aortic valve replacement (SAVR) in high risk patients with incremental costs considered acceptable from a U.S. perspective.
Study Blood Thinner Heart Attack Patients

The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers unique insight into the use, safety and effectiveness of blood thinners prasugrel and clopidogrel in hospitals across the United States. 

September 19, 2014 — A new study investigating different durations of triple therapy for anticoagulation after drug-eluting stent (DES) implantation demonstrated that six weeks of drug therapy was not superior to six months of therapy with regard to net clinical outcomes. ISAR-TRIPLE is the largest randomized trial to date investigating triple therapy after stenting and the first trial evaluating the duration of triple therapy. Findings were reported earlier this week at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

September 19, 2014 — According to a new study, peritoneal hypothermia is feasible for patients who have suffered ST-segment elevation myocardial infarction (STEMI). However, the procedure was associated with an increased rate of adverse events without reducing infarct size. These findings were reported at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium earlier this week.

New data from a landmark clinical trial found that after five years, transcatheter aortic valve replacement (TAVR) demonstrated a persistent mortality benefit, improved functional status, and resulted in a lower rate of repeat hospitalizations when compared with standard therapy for patients with severe aortic stenosis who are not candidates for surgery.

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The DKCRUSH-VI clinical trial is the first study to compare FFR-guided and angiography-guided stenting.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now